BRPI0509239A - regime de dosagem de combinação para eritropoietina - Google Patents
regime de dosagem de combinação para eritropoietinaInfo
- Publication number
- BRPI0509239A BRPI0509239A BRPI0509239-6A BRPI0509239A BRPI0509239A BR PI0509239 A BRPI0509239 A BR PI0509239A BR PI0509239 A BRPI0509239 A BR PI0509239A BR PI0509239 A BRPI0509239 A BR PI0509239A
- Authority
- BR
- Brazil
- Prior art keywords
- erythropoietin
- dosage regimen
- combination dosage
- epo
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"REGIME DE DOSAGEM DE COMBINAçãO PARA ERITROPOIETINA". A presente invenção fornece um regime de dosagem de combinação para eritropoietina (EPO). Mais particularmente, o regime de dosagem presente inclui administração de pelo menos um primeiro segmento de dosagem compreendendo uma primeira exposição à EPO capaz de estimular a produção de reticulócitos seguida por uma segunda exposição à EPO capaz de sustentar a maturação dos reticulócitos em neócitos, e finalmente, eritrócitos. Vantajosamente, o segmento de dosagem pode ser ciclado ou repetido, qualquer número de vezes e de acordo com qualquer esquema de tempo desejado, a fim de fornecer ou manter qualquer contagem de eritrócito total e/ou concentração de hemoglobina desejada . Métodos de tratamento empregando o regime de dosagem de combinação, bem como kits são da mesma forma fornecidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692304P | 2004-03-26 | 2004-03-26 | |
| PCT/US2005/009873 WO2005097167A1 (en) | 2004-03-26 | 2005-03-24 | Combination dosing regimen for erythropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509239A true BRPI0509239A (pt) | 2007-09-04 |
Family
ID=34964370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509239-6A BRPI0509239A (pt) | 2004-03-26 | 2005-03-24 | regime de dosagem de combinação para eritropoietina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050267026A1 (pt) |
| EP (1) | EP1737484A1 (pt) |
| JP (1) | JP2007530578A (pt) |
| KR (1) | KR20070015549A (pt) |
| CN (1) | CN1960745A (pt) |
| AU (1) | AU2005231307A1 (pt) |
| BR (1) | BRPI0509239A (pt) |
| CA (1) | CA2561222A1 (pt) |
| CR (1) | CR8705A (pt) |
| EA (1) | EA010889B1 (pt) |
| EC (1) | ECSP066885A (pt) |
| IL (1) | IL178288A0 (pt) |
| MX (1) | MXPA06011084A (pt) |
| NO (1) | NO20064908L (pt) |
| UA (1) | UA89630C2 (pt) |
| WO (1) | WO2005097167A1 (pt) |
| ZA (1) | ZA200608877B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150164991A1 (en) * | 2013-11-01 | 2015-06-18 | Vanderbilt University | Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367701A (zh) * | 1999-05-11 | 2002-09-04 | 奥索－麦克尼尔药物公司 | 红细胞生成素给药的药代动力学和药效模型 |
| NZ516735A (en) * | 1999-07-22 | 2004-01-30 | Aventis Pharma Inc | Multi-dose erythropoietin formulations containing benzethonium chloride as a preservative |
| DK1311285T4 (en) * | 2000-05-15 | 2017-07-24 | Hoffmann La Roche | Liquid pharmaceutical composition containing an erythropoietin derivative |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
-
2005
- 2005-03-24 MX MXPA06011084A patent/MXPA06011084A/es unknown
- 2005-03-24 CA CA002561222A patent/CA2561222A1/en not_active Abandoned
- 2005-03-24 US US11/088,284 patent/US20050267026A1/en not_active Abandoned
- 2005-03-24 CN CNA2005800171911A patent/CN1960745A/zh active Pending
- 2005-03-24 KR KR1020067022204A patent/KR20070015549A/ko not_active Application Discontinuation
- 2005-03-24 AU AU2005231307A patent/AU2005231307A1/en not_active Abandoned
- 2005-03-24 UA UAA200610352A patent/UA89630C2/ru unknown
- 2005-03-24 WO PCT/US2005/009873 patent/WO2005097167A1/en active Application Filing
- 2005-03-24 JP JP2007505184A patent/JP2007530578A/ja active Pending
- 2005-03-24 BR BRPI0509239-6A patent/BRPI0509239A/pt not_active IP Right Cessation
- 2005-03-24 EP EP05731453A patent/EP1737484A1/en not_active Ceased
- 2005-03-24 EA EA200601782A patent/EA010889B1/ru not_active IP Right Cessation
-
2006
- 2006-09-25 IL IL178288A patent/IL178288A0/en unknown
- 2006-09-26 EC EC2006006885A patent/ECSP066885A/es unknown
- 2006-10-25 ZA ZA200608877A patent/ZA200608877B/en unknown
- 2006-10-25 CR CR8705A patent/CR8705A/es not_active Application Discontinuation
- 2006-10-26 NO NO20064908A patent/NO20064908L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097167A1 (en) | 2005-10-20 |
| ZA200608877B (en) | 2008-06-25 |
| EP1737484A1 (en) | 2007-01-03 |
| IL178288A0 (en) | 2006-12-31 |
| CR8705A (es) | 2008-09-09 |
| AU2005231307A1 (en) | 2005-10-20 |
| MXPA06011084A (es) | 2007-03-21 |
| CA2561222A1 (en) | 2005-10-20 |
| ECSP066885A (es) | 2006-11-24 |
| EA010889B1 (ru) | 2008-12-30 |
| KR20070015549A (ko) | 2007-02-05 |
| US20050267026A1 (en) | 2005-12-01 |
| NO20064908L (no) | 2006-12-15 |
| CN1960745A (zh) | 2007-05-09 |
| EA200601782A1 (ru) | 2007-04-27 |
| JP2007530578A (ja) | 2007-11-01 |
| UA89630C2 (ru) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guest et al. | Sport nutrigenomics: personalized nutrition for athletic performance | |
| GT200100183A (es) | Derivados de quinolina y quinazolina. | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| CY1116041T1 (el) | Μεσα και μεθοδοι για τη θεραπευτικη αγωγη νεοπλασματικων νοσων | |
| CY1115350T1 (el) | Χρησεις αναστολεων της dpp iv | |
| ECSP066734A (es) | Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos | |
| CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
| BRPI0414435A (pt) | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios | |
| CY1115012T1 (el) | Μεθοδος συστηματικης εξετασης παρασκευασματων παρασιτου για αποτελεσματικοτητα στην αποτροπη και ελεγχο ασθενειων | |
| BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
| BRPI0608840B8 (pt) | composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação | |
| ECSP088139A (es) | Métodos para prevenir y tratar trastornos metabólicos y nuevos derivados de pirazol-o-glucósido | |
| WO2005117542A3 (en) | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments | |
| GT200500394A (es) | 18-metil-19-nor-17-oregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
| CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| NO20061184L (no) | Fremgangsmater og blandinger for behandling av herpes-infeksjoner | |
| BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
| UY28098A1 (es) | Derivados de anilinopirazol útiles en el tratamiento de la diabetes | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| Kim et al. | The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer | |
| BR112022022024A2 (pt) | Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit | |
| BRPI0509239A (pt) | regime de dosagem de combinação para eritropoietina | |
| DE602004021713D1 (de) | Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung | |
| CY1107243T1 (el) | Ανταγωνιστες χημειοκινικων υποδοχεων και μεθοδοι χρησης τους |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |